Αποτελέσματα Αναζήτησης
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
3 Ιαν 2023 · This statement from the International Antiviral Society–USA updates recommendations for the use of antiretroviral drugs to treat adults with established HIV infection and to prevent HIV infection among persons at risk.
24 Ιουλ 2024 · Cisgender women account for approximately half the 1.3 million new human immunodeficiency virus (HIV) infections that occur worldwide each year. 1 The first HIV preexposure prophylaxis...
9 Σεπ 2021 · Dapivirine, an NNRTI formulated as a monthly vaginal ring, was recently approved by the EMA for HIV prevention in women living in high HIV-burden settings. The ring is intended for adult women as a complementary approach to reduce the risk of HIV infection during vaginal sex.
23 Φεβ 2022 · We address four important topics: the geroscience underlying the high multimorbidity burden in older people with HIV; intersectionality of stigma and health-related quality of life; delayed HIV presentation; and how health systems can adapt to a population ageing with HIV and comorbidities.
11 Δεκ 2023 · Using drug therapy to block transmission and prevent HIV, HIV pre-exposure prophylaxis (PrEP) provides a critical intervention to reduce community spread and protect those with reasons to utilize PrEP.
21 Σεπ 2023 · This review summarizes the current literature on the efficacy of long-acting cabotegravir plus rilpivirine for the treatment of HIV-1, reasons to switch to injectable therapy, and barriers to switching. Recent Findings. Long-acting cabotegravir plus rilpivirine is safe and effective in maintaining HIV-1 virologic suppression.
